|Each enteric-coated tablet of PANFAST contains:
|Pantoprazole sodium sesquihydrate
Equivalent to Pantoprazole
Gastrointestinals; Proton pump inhibitors
Mechanism of Action
Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the H+,K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. Pantoprazole is the only proton pump inhibitor that binds to both cysteines 813 and 822 (the binding sites present on enzyme H+,K+-ATPase). Both these binding sites are actively involved in the blockade of enzyme activity and acid transport. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.
- Gastroesophageal Reflux Disease (GERD).
- Erosive esophagitis.
- Peptic Ulcer Disease (PUD).
- Zollinger Ellison syndrome.
- Helicobacter Pylori associated ulcers.
- Drug Induced Ulcers.
The recommended adult oral dose of Panfast
is 40 mg once daily. I n Zollinger Ellison syndrome recommended adult starting dose is 40 mg twice daily.
Pantoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation.
Pantoprazole is metabolized through the cytochrome P450 system. Clinically relevant interactions of pantoprazole
with other drugs with the same metabolic pathways are not expected.
has been well tolerated in both short-term and long-term trials.
MRP / Packaging
is available in a unit carton of 10 blister strips with 10 tablets in each strip.
- Not associated with recurrent MI in patients receiving clopidogrel with compared to omeprazole, lansoprazole & rabeprazole.
- Does not inhibit cytochrome P450 2C19 isoenzyme.
- Thus, does not alter clopidogrel's effects.